Zocchi et al. demonstrated that HL-MSCs, by secreting TGF-β, are able to downregulate NKG2D expression on effector T cells [85] and by expressing ADAM10 to decrease NKG2D-L in tumor cells, thus reducing the anticancer immune response [85]. The gene discussed is KLRK1; the disease is neoplasm.